CC BY
3JOURNAL OF CARDIORESPIRATORY RESEARCH
ЖУРНАЛ КАРДИОРЕСПИРАТОРНЫХ ИССЛЕДОВАНИЙ
УДК 615.83:616.12-005.8
Хусаинова Мунира Алишеровна
ассистент кафедры пропедевтики внутренних болезней Самаркандский Государственный Медицинский Университет Самарканд, Узбекистан
ОЗОНОТЕРАПИЯ В ВОССТАНОВИТЕЛЬНОМ ЛЕЧЕНИИ ПАЦИЕНТОВ С ИШЕМИЧЕСКОЙ БОЛЕЗНЬЮ СЕРДЦА
For citation: Khusainova M.A OZONETHERAPY IN RESTORATIVE TREATMENT PATIENTS WITH CORONARY HEART DISEASE. Journal of cardiorespiratory research. 2022, vol 3, issue 4, pp.87-90
http: //dx. doi.org/10.5281/zenodo.7366228
АННОТАЦИЯ
Лечение озоном относится к физиотерапевтическим методам и, в первую очередь, должно способствовать эффективности основного курса лечения. Ионизированный кислород оказывает глубинное стабилизирующее влияние на процессы обмена в тканях сердца и сосудов. С помощью сеансов озонотерапии удается существенно повысить уровень качества жизни для больного человека. Проблема лечения больных ишемической болезнью сердца (ИБС) является актуальной в связи с ростом частоты заболевания. ИБС — заболевание сердечной мышцы, обусловленное нарушением равновесия между коронарным кровотоком и метаболическими потребностями сердечной мышцы. В последние годы для нормализации кислородного обеспечения тканей начали использовать медицинский озон. Изменяя структуру липидов мембран, озон увеличивает деформируемость эритроцитов и тем самым улучшает реологические свойства крови. Он обладает сосудорасширяющим действием, значительно улучшает отдачу кислорода оксигемоглобином.
Ключевые слова: ишемическая болезнь сердца, озонотерапия, озонированный физиологический раствор, ректальная инсуффляция, санаторное лечение.
Khusainova Munira Alisherovna
assistant of the Department of Propaedeutics of Internal Diseases, Samarkand State Medical University Samarkand, Uzbekistan
OZONETHERAPY IN RESTORATIVE TREATMENT PATIENTS WITH CORONARY HEART DISEASE
ANNOTATION
Ozone treatment refers to physiotherapeutic methods and, first of all, should contribute to the effectiveness of the main course of treatment. Ionized oxygen has a profound stabilizing effect on the metabolic processes in the tissues of the heart and blood vessels. With the help of ozone therapy sessions, it is possible to significantly improve the quality of life for a sick person. The problem of treating patients with coronary heart disease (CHD) is urgent due to the increasing frequency of the disease. CHD is a disease of the heart muscle caused by a violation of the balance between coronary blood flow and the metabolic needs of the heart muscle. In recent years, medical ozone has been used to normalize the oxygen supply of tissues. By changing the structure of membrane lipids, ozone increases the deformability of erythrocytes and thereby improves the rheological properties of blood. It has a vasodilating effect, significantly improves the oxygen output by oxyhemoglobin.
Keywords: coronary heart disease, ozone therapy, ozonated saline solution, rectal insufflation, sanatorium treatment.
Khusainova Munira Alisherovna
Ichki kasalliklar propedevtikasi kafedrasi assistenti Samarqand Davlat Tibbiyot Universiteti Samarqand, O'zbekiston
OZONOTERAPIYA YURAK ISHEMIK KASALLIGI BOR BEMORLARDA DAVOLASH USULI SIFATIDA
ANNOTATSIYA
Ozonoterapiya fizioterapevtik davolash usullaridan biri bo'lib, birinchi navbatda asosiy davolash kursi effektivligini ta'minlaydi. Ionlangan kislorod yurak va qon tomirlari to'qimalaridagi metabolik jarayonlarga chuqur stabillashgan ta'sir ko'rsatadi. Ozonoterapiya yordamida bemorlarning hayot sifatini sezilarli darajada yaxshilash mumkin. Yurak ishemik kasalligi (YIK) bilan og'rigan bemorlarni davolash muammosi kasallikning ko'payishi bilan bog'liq. YIK-bu koronar qon oqimi va yurak mushagining metabolik ehtiyojlari o'rtasidagi muvozanatning buzilishi natijasida kelib chiqqan yurak mushagi kasalligi. So'nggi yillarda tibbiy ozon to'qimalarni kislorod bilan ta'minlashni normallashtirish uchun ishlatila boshlandi. Membrana lipidlarining tuzilishini o'zgartirib, ozon eritrotsitlarning deformatsiyasini oshiradi va shu bilan qonning reologik xususiyatlarini yaxshilaydi. U vazodilatator ta'siriga ega, kislorodning oksigemoglobin bilan qaytarilishini sezilarli darajada yaxshilaydi.
Kalit so'zlar: yurak ishemik kasalligi, ozonoterapiya, ozonlangan fiziologik eritma, rektal insufflyatsiya, sanatoriy davolash.
The main objectives of the rehabilitation treatment of patients with ischemic heart disease (CHD) are normalization of blood supply to ischemic areas of the myocardium, reduction of the degree of ischemic remodeling, cytoprotection of cardiomyocytes, prevention of endothelial coronary dysfunction, improvement of blood rheology and correction of lipid metabolism. In recent years, medical ozone has been used to normalize the oxygen supply of tissues. By changing the structure of membrane lipids, ozone increases the deformability of erythrocytes and thereby improves rheological properties of blood. It has a vasodilating effect, significantly improves the oxygen output by oxyhemoglobin. The above poses a task for clinicians to further study the effect of the ozone therapy method both in the form of mono- and as part of traditional therapy in patients with coronary heart disease. In addition, the high degree of allergization of the population, the need for long-term use of medications for combined diseases of the cardiovascular system in connection with the aging of the population serve as the basis for the search, development and introduction of new non-drug methods of their treatment. Such methods include ozone therapy. Medical ozone, being a natural non-drug physical factor, is able to resist oxidative stress due to stimulation of the antioxidant system, that is, it has an indirect antioxidant activity. The value of ozone in coronary heart disease is to improve oxygen delivery and metabolic processes, which affects the redox reactions occurring in the respiratory chain of mitochondria, improves the rheological properties of blood, reduces the total peripheral vascular resistance, normalizes lipid metabolism, improves microcirculation in tissues, increases nonspecific resistance of the body. In addition, it contributes to the better use of arterial oxygen in relieving hypoxic conditions and restoring cell functions.
Purpose of the work
To study the clinical efficacy of ozone therapy at the stage of rehabilitation treatment of patients with coronary heart disease.
Materials and methods
The study was open and randomized, duration — 12 days. The examination of 40 patients with coronary heart disease — angina pectoris of functional classes (FC) I and II aged 42 to 78 years (average age 57.8 ± 0.6 years) was carried out. There were men 51.0%, women — 49.0%. For a comparative assessment of the effectiveness of the therapeutic effect of OST, the first main group (MG-1) was allocated in the amount of 15 people, who were injected intravenously with an ozonated saline solution in the amount of 200 ml with an ozone concentration of 2.5-3.0 mg / l, obtained on a medical ozonizer of the Medozon company 2-3 times per week (7 procedures in total). The second main group (MG-2) is represented by 13 patients who received antianginal drugs and an ozone-oxygen mixture in the form of monotherapy in the same mode as patients of MG-1. The first control group (CG-1) consisted of 8 people who received conventional treatment without ozonetherapy. The second control group (CG-2) included 5 people who were prescribed the same treatment as the MG-1 patients, but only the ozonetherapy method was replaced by placebo (200 ml saline solution was administered intravenously). Prior to inclusion in the study, 6 (15.5%) patients did not take medications. The remaining patients (34 people — 84.5%) received basic drug therapy in an individually selected dose for arterial hypertension (AH) and coronary heart disease in the form of beta-blockers (6 people — 19.1%) or prolonged nitrates (5 people - 15.3%). Patients with coronary heart disease (stable angina pectoris FC II) in the amount of 15 (45.0%) people with hypertension and left ventricular hypertrophy, angiotensin converting enzyme (ACE) inhibitors were taken. Combination of beta-blockers with ACE inhibitors were used by 7 (20.6%) people.
Results
During clinical observation of patients of the examined groups during treatment, attention was paid to the dynamics of the main feature of coronary heart disease — pain syndrome in the heart area. At the same time, its frequency, duration and severity were taken into account. By the end of treatment, anginal attacks in MG-1 in 9 (63.6%) patients, decreased in 5 (36.4%), and in the MG—2 group these indicators were 60.0 and 38.0%, respectively. In the control groups, anginal attacks stopped only in 3 (33.3%) people. The rate of cessation of anginal seizures in patients of the main groups compared with CG-1 was statistically significant. The inclusion of an ozone-oxygen mixture in the complex treatment of patients with coronary heart disease, as well as its use in the form of monotherapy, provided statistically there is also a significant positive effect on the frequency and duration of anginal attacks, especially in the first 5 days of treatment compared to the control. Antianginal efficacy in the examined individuals of the main and control groups was assessed by the tolerance of physical activity by determining the walking distance (in meters) on flat terrain at an average pace in patients with coronary artery disease (stable angina pectoris FC II) before the onset of angina pectoris at the beginning and end of the recovery period. It was noted that against the background of treatment with the use of OZT, a statistically significant increase in walking distance was determined in the main groups, respectively, by 33.0 and 23.2%, while in CG-1 it was only 10.3%. At the same time, the frequency of anginal attacks per week in MG-1 and in OG-2 by the end of treatment decreased from 4.3 ± 0.8 to 1.2 ±0.3 and from 4.6 ± 0.9 to 1.6 ± 0.5, respectively, which was statistically significant compared to CG-1 (p < 0.001).By the end of treatment, the cessation of angina seizures was observed only in 35.0% of patients receiving placebo, and in the group of examined individuals who received OZT in complex treatment, this indicator was higher — 63.6%, which indicated a statistically significant difference.
It should be noted that with the cessation of anginal seizures or with a decrease in their frequency and duration, it became possible to reduce the dose of antianginal drugs or their complete withdrawal in some of the examined patients. Positive dynamics of subjective and objective manifestations after 5 days and by the end of treatment (12 days) was noted in all four groups of patients. The frequency of positive clinical effect between the control and main groups of patients by the end of treatment was p < 0.001, the differences are statistically significant.
ECG indicators in patients receiving ozonetherapy both in complex treatment (AH-1) and in the form of monotherapy (AH-2) indicated an improvement in the processes of myocardial repolarization (restoration of the amplitude of the T wave in patients with negative or two-phase T waves, an increase in the amplitude of the R wave), a decrease or complete disappearance of extrasystoles, a decrease in left ventricular overload. Moreover, the most pronounced positive dynamics was recorded in MG-1.
A positive therapeutic effect was obtained in patients of the main groups of coronary heart disease in combination with hypertension. The course of ozonetherapy in MG-1 contributed to statistically significant decrease in blood pressure (BP), both systolic (157.2 ± 2.85 — 136.9 ± 1.48 mmHg) and diastolic (95.6 ± 1.48 — 82.7±0.78 mm Hg). A significant statistically significant decrease in blood pressure by the end of treatment was also noted in MG-2. In CG-1 and in the group of patients receiving placebo (CG-2), blood pressure indicators remained unchanged. In during the treatment of these individuals, the target level was reached in 70.0% of cases. In patients with persistent hypertension, the use of ozonetherapy was effective only in combination with antihypertensive drugs, which in some cases were used in smaller doses.
When comparing the baseline parameters of the lipid spectrum of blood serum of patients with CHD with similar data of healthy individuals marked changes in lipid metabolism in the direction of improvement. The content of total cholesterol in the blood serum of patients with MG-1 after On day 12, it decreased statistically significantly — from 5.78 ± 0.21 to 4.9 ± 0.17 mmol/L. The concentration of low-density lipoprotein cholesterol decreased by the end of treatment from 3.70 ± 0.21 to 2.86 ± 0.11 mmol/l. In this group, there was also a statistically significant decrease in triglycerides. In the group of patients with monotherapy also revealed positive dynamics of all lipidogram indicators, which statistically significantly differed from those of patients treated with conventional methods. The average duration of remission in the main groups was approximately the same and amounted, respectively, 7.5 ± 0.5 and 6.8 ± 0.5 months, and in the control — 4.4 ± 0.7 months.
Discussion
The obtained research results indicate the high efficiency of the ozone therapy method as a training factor for increasing the functional reserves of the cardiovascular system. The adaptive capacity of the body in response to physical exertion under the influence of ozone therapy has increased in most patients, which is an important reserve in increasing the effectiveness of their rehabilitation. A comprehensive
References/Спнсок aHTepaiypbi/Iqtiboslar
clinical, laboratory and instrumental examination confirmed the concept that the use of ozone therapy for angina pectoris significantly increases the effectiveness of conventional treatment in a temperate continental climate Of the Republic of Uzbekistan by activating oxygen supply mechanisms, increasing the functional reserves of the cardiovascular system, and stimulating adaptive systems.
Conclusion
1. The inclusion of ozone therapy in the restorative complex treatment of patients with coronary heart disease has a positive effect on the clinical manifestations of the disease and improves the blood lipid spectrum, which reduces the risk of cardiovascular complications.
2. Treatment with an ozone-oxygen mixture provides an antihypertensive effect, the average daily level of systolic and diastolic blood pressure significantly decreased in patients of the main group.
3. Parenteral administration technique the ozone-oxygen mixture expands the possibilities of treating patients with coronary heart disease with stable angina pectoris (FC I and II), including those with a high risk of complications and in the presence of concomitant diseases.
4. Ozone therapy is a highly effective and promising natural non-drug methods of restorative treatment of patients with coronary heart disease.
1. Agababyan, I., Soliyeva, S., & Ismoilova, Y. (2021). Condition Of Coronary Arteries And Change Of Lipid Profile In Coronary Heart Disease. Annals Of The Romanian Society For Cell Biology, 207-213.
2. Alisherovna, K. M., & Tatlibayevich, Y. S. (2021). Assessment Of Risk Factors For Arterial Hypertension Hypertension In Pregnant Women. Central Asian Journal Of Medical And Natural Sciences, 2(3), 214-217.
3. Alisherovna, K. M., Alisherovich, B. Z., Ilyosxonovich, K. I., & Oybekovna, E. E. (2022). Changes In Hemodynamics Of The Cardiovascular System In Patients With Fibrosis Alveolitis. Spectrum Journal Of Innovation, Reforms And Development, 4, 203-209.
4. Buribayevich, N. M. (2022). Applications The Drug Nicomex At Treatment Of Patients With Chronic Heart Failure And Type 2 Diabetes Mellitus. Web Of Scientist: International Scientific Research Journal, 3(5), 597-605.
5. Buribayevich, N. M. (2022). Treatment Of Chronic Heart Failure In Patients With Type 2 Diabetes Mellitus. Central Asian Journal Of Medical And Natural Sciences, 3(1), 183-186.
6. Djamshedovna, K. D. (2021). Echocardiography Signs F Chf In Patients With Essential Hypertension. Web Of Scientist: International Scientific Research Journal, 2(11), 192-196.
7. Gafforov, X. (2021). Jigar Sirrosi Kasalligida Yurakning Sistolik Va Diastolik Disfunktsiyasining Ahamiyati. Журнал Кардиореспираторных Исследований, 2(1), 67-69.
8. Khabibovna, Y. S., & Abdukodirovna, A. S. (2021). Changes In The Diastolic Function Of The Right Ventricle In Arterial Hypertension. Web Of Scientist: International Scientific Research Journal, 2(11), 161-169.
9. Shodikulova, G. Z., Pulatov, U. S., Ergashova, M. M., Tairova, Z. K., & Atoev, T. T. (2021). The Correlation Among Osteoporosis, Calcium-Phosphore Metabolism And Clinical Symptoms Of Main Disease In Patients With Rheumatoid Arthritis. Annals Of The Romanian Society For Cell Biology, 4185-4190.
10. Toshtemirovna, E. M. M., Alisherovna, K. M., Totlibayevich, Y. S., & Muxtorovna, E. M. (2022). Hearts In Rheumatoid Arthritis: The Relationship With Immunological Disorders. Spectrum Journal Of Innovation, Reforms And Development, 4, 34-41.
11. Xudoyberdiyevich, G. X. (2022). Heart Failure, Diabetes Mellitus, Beta Blockers And The Risk Of Hypoglycemia. Spectrum Journal Of Innovation, Reforms And Development, 4, 42-48.
12. Yarmatov, S. T. (2021). Yurak Ishemik Kasalligi Va Bachadon Miomasi Bo'lgan Bemorlarni Davolashda Antikougulyant Va Antitrombositar Terapiyani O'tkazish Bo'yicha Klinik Kuzatuvni Olib Borish. Scientific Progress, 2(3), 792-797.
13. Yarmatov, S. T., & Xusainova, M. A. (2021). Yurak Ishemik Kasalligi Mavjud Bo'lgan Bemorlarda. Scientific Progress, 2(3), 785-791.
14. Yarmatov, S. T., & Yarmahammadov, U. K. (2022). Semizlik-Zamonaviy Tibbiyotda Dolzarb Muammo Sifatida Qolmoqda. Scientific Progress, 3(4), 1196-1203.
15. Zikriyaevna, S. G., & Muhtorovna, E. M. (2019). The Features Of The Early Diagnostics Of Osteoporosis In Patients With Rheumatoid Arthritis. Достижения Науки И Образования, (12 (53)), 110-112.
16. Камолова, Д. Ж. (2022). Structural-Geometrical Changes Of The Myocardium And The Particularities Of The Left Ventricle Of The Heart In A Pregnant Women With A Different Types Of Arterial Hypertension. Журнал Кардиореспираторных Исследований, 3(1).
17. Норматов, М. Б. (2022). Efficacy Of Amlodipine In Arterial Hypertension Combined With Type 2 Diabetes Mellitus. Журнал Кардиореспираторных Исследований, 3(1).
18. Ярмухаммедова, С. (2020). Оценка Признаков Диастолической Дисфункции Правого Желудочка У Больных С Артериальной Гипертонией. Журнал Кардиореспираторных Исследований, 1(2), 88-92.
19. Элламонов С. Н. и др. Факторы прогрессирования артериальной гипертензии у больных в коморбидности с сахарным диабетом 2 типа //Журнал кардиореспираторных исследований. - 2021. - Т. 2. - №. 2.
20. Ташкенбаева Э. Н. и др. АССОЦИИРОВАННЫЕ ФАКТОРЫ РИСКА КАРДИОВАСКУЛЯРНЫХ СОБЫТИЙ У ЖЕНЩИН В ПОСТМЕНОПАУЗАЛЬНОМ ПЕРИОДЕ //Журнал кардиореспираторных исследований. - 2020. - Т. 1. - №. 3.
21. Мирзаев Р. З., Ташкенбаева Э. Н., Абдиева Г. А. ПРОГНОСТИЧЕСКИЕ КЛИНИЧЕСКИЕ МАРКЕРЫ ПОЧЕЧНОЙ НЕДОСТАТОЧНОСТИ ПРИ МЕТАБОЛИЧЕСКОМ СИНДРОМЕ //Журнал кардиореспираторных исследований. - 2022. - №. SI-2.
22. Ташкенбаева Э. Н. и др. Механизмы кардиозащитных эффектов десфлурана и севофлурана во время реперфузии //Журнал кардиореспираторных исследований. - 2021. - Т. 2. - №. 2.
23. Кадирова Ф., Рахимова М., Ташкенбаева Э. ХРОНИЧЕСКАЯ СЕРДЕЧНАЯ НЕДОСТАТОЧНОСТЬ С СОХРАНЁННОЙ И ПРОМЕЖУТОЧНОЙ ФРАКЦИЕЙ ВЫБРОСА ЛЕВОГО ЖЕЛУДОЧКА, ПУТИ ЕЁ КОРРЕКЦИИ (ОБЗОР) //Журнал кардиореспираторных исследований. - 2020. - Т. 1. - №. 2. - С. 28-34.
24. Ташкенбаева Э. и др. РАСПРОСТРАНЕННОСТЬ МЕТАБОЛИЧЕСКОГО СИНДРОМА У ПАЦИЕНТОВ С ИШЕМИЧЕСКОЙ БОЛЕЗНЬЮ СЕРДЦА //Журнал кардиореспираторных исследований. - 2021. - Т. 2. - №. 1. - С. 85-88.
25. Абдувакилов Ж., Ризаев Ж. Биохимические маркеры соединительной ткани у больных хроническим воспалительным пародонтитом на фоне метаболического синдрома //Stomatologiya. - 2018. - Т. 1. - №. 1 (70). - С. 11-14.
26. Ziyadullaev S. et al. The effect of budesonide on the quality of life in patients with bronchial asthma //European Journal of Molecular & Clinical Medicine. - 2020. - Т. 7. - №. 2. - С. 1760-1766.
27. Абдуллаев Д., Гадаев А., Ризаев Ж. Матриксные металлопротеиназы у больных с болезнями пародонта и хронической сердечной недостаточностью //Stomatologiya. - 2017. - Т. 1. - №. 2 (67). - С. 104-106.
28. Зиядуллаев Ш. Х. и др. Роль некоторых регуляторных цитокинов в иммунопатогенезе экзогенных аллергических альвеолитов //Здобутки юнтчно! i експериментально! медицини. - 2017. - №. 1. - С. 38-41.
29. Зиядуллаев С. и соавт. Влияние будесонида на качество жизни больных бронхиальной астмой //Европейский журнал молекулярной и клинической медицины. - 2020. - Т. 7. - №. 2. - С. 1760-1766 гг.
